Marinus Pharmaceuticals Inc

Most Recent

  • uploads///Marinus risks
    Company & Industry Overviews

    Key Risks Facing Marinus Pharmaceuticals in December 2017

    Since inception in 2003, Marinus Pharmaceuticals (MRNS) has focused on the development of ganaxalone.

    By Kenneth Smith
  • uploads///Fei
    Company & Industry Overviews

    Why Axovant Sciences Stock Rose in Week Ended June 8

    On June 6, Axovant Sciences entered into an agreement to develop and sell Oxford BioMedica’s OXB-102 for the treatment of Parkinson’s disease.

    By Daniel Collins
  • uploads///ganaxalone pre
    Company & Industry Overviews

    Ganaxalone Faces Stiff Competition from Other Drugs under Development

    Marinus Pharmaceuticals (MRNS) has initiated a phase two study to test the feasibility of ganaxalone in patients suffering from refractory status epilepticus (or RSE). Data from this study is expected in 2018.

    By Kenneth Smith
  • uploads///Marinus RD Trend
    Company & Industry Overviews

    Why Ganaxalone Is a Promising Drug Candidate

    Marinus Pharmaceuticals (MRNS) announced phase two results from its open-label study evaluating the efficacy of ganaxalone in patients suffering from CDKL5 deficiency disorder (or CDD) in September 2017.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.